Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.

Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LA, Kolar G, Squillace S, Boccella S, Walker JK, Pendleton A, Spiegel S, Neumann WL, Vanderah TW, Salvemini D.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10557-10562. doi: 10.1073/pnas.1820466116. Epub 2019 May 8.

PMID:
31068460
2.

Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons.

Coppi E, Cherchi F, Fusco I, Failli P, Vona A, Dettori I, Gaviano L, Lucarini E, Jacobson KA, Tosh DK, Salvemini D, Ghelardini C, Pedata F, Di Cesare Mannelli L, Pugliese AM.

Pain. 2019 May;160(5):1103-1118. doi: 10.1097/j.pain.0000000000001488.

PMID:
31008816
3.

Activation of Sphingosine-1-Phosphate Receptor 1 in the Spinal Cord Produces Mechanohypersensitivity Through the Activation of Inflammasome and IL-1β Pathway.

Doyle TM, Chen Z, Durante M, Salvemini D.

J Pain. 2019 Feb 23. pii: S1526-5900(18)30585-6. doi: 10.1016/j.jpain.2019.02.007. [Epub ahead of print]

PMID:
30802544
4.

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djz011. [Epub ahead of print]

PMID:
30715378
5.

Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity.

Branca JJV, Maresca M, Morucci G, Becatti M, Paternostro F, Gulisano M, Ghelardini C, Salvemini D, Di Cesare Mannelli L, Pacini A.

Oncotarget. 2018 May 4;9(34):23426-23438. doi: 10.18632/oncotarget.25193. eCollection 2018 May 4.

6.

Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain.

Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, Braden K, Lauro F, Giancotti LA, Harada CM, Yadav R, Xiao WH, Lionberger JM, Neumann WL, Bennett GJ, Weng HR, Spiegel S, Salvemini D.

J Exp Med. 2018 May 7;215(5):1301-1313. doi: 10.1084/jem.20170584. Epub 2018 Apr 27.

7.

Targeting metabotropic adenosine receptors for neuropathic pain: Focus on A2A.

Luongo L, Salvemini D.

Brain Behav Immun. 2018 Mar;69:60-61. doi: 10.1016/j.bbi.2018.02.014. Epub 2018 Mar 1. No abstract available.

PMID:
29499304
8.

The Neurotoxin DSP-4 Induces Hyperalgesia in Rats that is Accompanied by Spinal Oxidative Stress and Cytokine Production.

Touchette JC, Little JW, Wilken GH, Salvemini D, Macarthur H.

Neuroscience. 2018 Apr 15;376:13-23. doi: 10.1016/j.neuroscience.2018.01.058. Epub 2018 Feb 5.

PMID:
29421433
9.

Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms.

Wahlman C, Doyle TM, Little JW, Luongo L, Janes K, Chen Z, Esposito E, Tosh DK, Cuzzocrea S, Jacobson KA, Salvemini D.

Pain. 2018 Jun;159(6):1025-1034. doi: 10.1097/j.pain.0000000000001177.

10.

Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma.

Cuzzocrea S, Doyle T, Campolo M, Paterniti I, Esposito E, Farr SA, Salvemini D.

J Neurotrauma. 2018 Jul 1;35(13):1452-1466. doi: 10.1089/neu.2017.5391. Epub 2018 Apr 17.

PMID:
29310513
11.

Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain.

Salvemini D, Jacobson KA.

Expert Opin Ther Pat. 2017 Aug;27(8):967. doi: 10.1080/13543776.2017.1341018. Epub 2017 Jun 20. No abstract available.

12.

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Grenald SA, Doyle TM, Zhang H, Slosky LM, Chen Z, Largent-Milnes TM, Spiegel S, Vanderah TW, Salvemini D.

Pain. 2017 Sep;158(9):1733-1742. doi: 10.1097/j.pain.0000000000000965.

13.

Exploring the Role of N6-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇.

Petrelli R, Scortichini M, Kachler S, Boccella S, Cerchia C, Torquati I, Del Bello F, Salvemini D, Novellino E, Luongo L, Maione S, Jacobson KA, Lavecchia A, Klotz KN, Cappellacci L.

J Med Chem. 2017 May 25;60(10):4327-4341. doi: 10.1021/acs.jmedchem.7b00291. Epub 2017 May 5.

14.

Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2017 Apr 13;60(7):3109-3123. doi: 10.1021/acs.jmedchem.7b00141. Epub 2017 Mar 20.

15.

Nitroxidative Signaling Mechanisms in Pathological Pain.

Grace PM, Gaudet AD, Staikopoulos V, Maier SF, Hutchinson MR, Salvemini D, Watkins LR.

Trends Neurosci. 2016 Dec;39(12):862-879. doi: 10.1016/j.tins.2016.10.003. Epub 2016 Nov 12. Review.

16.

Cancer and orofacial pain.

Romero-Reyes M, Salvemini D.

Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21(6):e665-e671. Review.

17.

The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, Forte BL, Staatz WD, Bui L, Neumann WL, Mantyh PW, Salvemini D, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Nov;157(11):2605-2616.

18.

Transient Receptor Potential Melastatin-3 (TRPM3) Mediates Nociceptive-Like Responses in Hydra vulgaris.

Malafoglia V, Traversetti L, Del Grosso F, Scalici M, Lauro F, Russo V, Persichini T, Salvemini D, Mollace V, Fini M, Raffaeli W, Muscoli C, Colasanti M.

PLoS One. 2016 Mar 14;11(3):e0151386. doi: 10.1371/journal.pone.0151386. eCollection 2016.

19.

Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.

Tosh DK, Ciancetta A, Warnick E, O'Connor R, Chen Z, Gizewski E, Crane S, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2016 Apr 14;59(7):3249-63. doi: 10.1021/acs.jmedchem.5b01998. Epub 2016 Feb 18.

20.

Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Janes K, Symons-Liguori AM, Jacobson KA, Salvemini D.

Br J Pharmacol. 2016 Apr;173(8):1253-67. doi: 10.1111/bph.13446. Epub 2016 Mar 6. Review.

21.

Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors.

Carlin JL, Tosh DK, Xiao C, Piñol RA, Chen Z, Salvemini D, Gavrilova O, Jacobson KA, Reitman ML.

J Pharmacol Exp Ther. 2016 Feb;356(2):474-82. doi: 10.1124/jpet.115.229872. Epub 2015 Nov 25.

22.

Pain and Poppies: The Good, the Bad, and the Ugly of Opioid Analgesics.

Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM.

J Neurosci. 2015 Oct 14;35(41):13879-88. doi: 10.1523/JNEUROSCI.2711-15.2015. Review.

23.

Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.

Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA.

Medchemcomm. 2015;6:555-563.

24.

Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.

Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

ACS Med Chem Lett. 2015 May 20;6(7):804-8. doi: 10.1021/acsmedchemlett.5b00150. eCollection 2015 Jul 9.

25.

Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain.

Tosh DK, Padia J, Salvemini D, Jacobson KA.

Purinergic Signal. 2015 Sep;11(3):371-87. doi: 10.1007/s11302-015-9459-2. Epub 2015 Jun 27.

26.

Chronic pain: new insights in molecular and cellular mechanisms.

Luongo L, Malcangio M, Salvemini D, Starowicz K.

Biomed Res Int. 2015;2015:676725. doi: 10.1155/2015/676725. Epub 2015 Mar 23. No abstract available.

27.

Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Ford A, Castonguay A, Cottet M, Little JW, Chen Z, Symons-Liguori AM, Doyle T, Egan TM, Vanderah TW, De Koninck Y, Tosh DK, Jacobson KA, Salvemini D.

J Neurosci. 2015 Apr 15;35(15):6057-67. doi: 10.1523/JNEUROSCI.4495-14.2015. Erratum in: J Neurosci. 2015 Jun 10;35(23):8971.

28.

In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.

Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2014 Dec 11;57(23):9901-14. doi: 10.1021/jm501021n. Epub 2014 Nov 25.

29.

Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.

Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, Xie J, Luongo L, Tosh DK, Maione S, Bannister K, Dickenson AH, Vanderah TW, Porreca F, Jacobson KA, Salvemini D.

Brain. 2015 Jan;138(Pt 1):28-35. doi: 10.1093/brain/awu330. Epub 2014 Nov 19.

30.

A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.

Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, Salvemini D.

Pain. 2014 Dec;155(12):2560-7. doi: 10.1016/j.pain.2014.09.016. Epub 2014 Sep 19.

31.

Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy.

Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, Salvemini D.

Brain Behav Immun. 2015 Feb;44:91-9. doi: 10.1016/j.bbi.2014.08.010. Epub 2014 Sep 8.

32.

The effect of peroxynitrite decomposition catalyst MnTBAP on aldehyde dehydrogenase-2 nitration by organic nitrates: role in nitrate tolerance.

Mollace V, Muscoli C, Dagostino C, Giancotti LA, Gliozzi M, Sacco I, Visalli V, Gratteri S, Palma E, Malara N, Musolino V, Carresi C, Muscoli S, Vitale C, Salvemini D, Romeo F.

Pharmacol Res. 2014 Nov;89:29-35. doi: 10.1016/j.phrs.2014.07.007. Epub 2014 Aug 28.

PMID:
25174989
33.

Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.

Tosh DK, Paoletta S, Chen Z, Moss SM, Gao ZG, Salvemini D, Jacobson KA.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3302-6. doi: 10.1016/j.bmcl.2014.06.006. Epub 2014 Jun 11.

34.

The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.

Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, Cuzzocrea S, Bieberich E, Obeid L, Petrache I, Nicol G, Neumann WL, Salvemini D.

J Biol Chem. 2014 Jul 25;289(30):21082-97.

35.

DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.

Rajagopalan P, Tracey H, Chen Z, Bandyopadhyaya A, Veeraraghavan S, Rajagopalan DR, Salvemini D, McPhee I, Viswanadha S, Rajagopalan R.

Bioorg Med Chem Lett. 2014 Jul 15;24(14):3088-91. doi: 10.1016/j.bmcl.2014.05.016. Epub 2014 May 14.

PMID:
24863744
36.

Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congeners.

Paoletta S, Tosh DK, Salvemini D, Jacobson KA.

PLoS One. 2014 May 23;9(5):e97858. doi: 10.1371/journal.pone.0097858. eCollection 2014.

37.

Mitotoxicity in distal symmetrical sensory peripheral neuropathies.

Bennett GJ, Doyle T, Salvemini D.

Nat Rev Neurol. 2014 Jun;10(6):326-36. doi: 10.1038/nrneurol.2014.77. Epub 2014 May 20. Review. Erratum in: Nat Rev Neurol. Aug;10(8):428.

38.

Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.

Janes K, Doyle T, Bryant L, Esposito E, Cuzzocrea S, Ryerse J, Bennett GJ, Salvemini D.

Pain. 2013 Nov;154(11):2432-40. doi: 10.1016/j.pain.2013.07.032. Epub 2013 Jul 25.

39.

Posttranslational nitration of tyrosine residues modulates glutamate transmission and contributes to N-methyl-D-aspartate-mediated thermal hyperalgesia.

Muscoli C, Dagostino C, Ilari S, Lauro F, Gliozzi M, Bardhi E, Palma E, Mollace V, Salvemini D.

Mediators Inflamm. 2013;2013:950947. doi: 10.1155/2013/950947. Epub 2013 Jun 20.

40.

Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.

Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2013 Jul 25;56(14):5949-63. doi: 10.1021/jm4007966. Epub 2013 Jul 3.

41.

Spinal mitochondrial-derived peroxynitrite enhances neuroimmune activation during morphine hyperalgesia and antinociceptive tolerance.

Little JW, Cuzzocrea S, Bryant L, Esposito E, Doyle T, Rausaria S, Neumann WL, Salvemini D.

Pain. 2013 Jul;154(7):978-86. doi: 10.1016/j.pain.2013.02.018. Epub 2013 Feb 27.

42.

NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice.

Doyle T, Esposito E, Bryant L, Cuzzocrea S, Salvemini D.

Neuroscience. 2013 Jun 25;241:1-9. doi: 10.1016/j.neuroscience.2013.02.042. Epub 2013 Feb 27.

43.

Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications.

Salvemini D, Kim SF, Mollace V.

Am J Physiol Regul Integr Comp Physiol. 2013 Apr 1;304(7):R473-87. doi: 10.1152/ajpregu.00355.2012. Epub 2013 Feb 6. Review.

44.

Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism.

Finley A, Chen Z, Esposito E, Cuzzocrea S, Sabbadini R, Salvemini D.

PLoS One. 2013;8(1):e55255. doi: 10.1371/journal.pone.0055255. Epub 2013 Jan 25.

45.

Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain.

Salvemini D, Doyle T, Kress M, Nicol G.

Trends Pharmacol Sci. 2013 Feb;34(2):110-8. doi: 10.1016/j.tips.2012.12.001. Epub 2013 Jan 12. Review.

PMID:
23318139
46.

Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway.

Little JW, Chen Z, Doyle T, Porreca F, Ghaffari M, Bryant L, Neumann WL, Salvemini D.

J Neurosci. 2012 Aug 8;32(32):10797-808. doi: 10.1523/JNEUROSCI.6345-11.2012.

47.

Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain.

Doyle T, Chen Z, Muscoli C, Bryant L, Esposito E, Cuzzocrea S, Dagostino C, Ryerse J, Rausaria S, Kamadulski A, Neumann WL, Salvemini D.

J Neurosci. 2012 May 2;32(18):6149-60. doi: 10.1523/JNEUROSCI.6343-11.2012.

48.

Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, Jacobson KA, Salvemini D.

FASEB J. 2012 May;26(5):1855-65. doi: 10.1096/fj.11-201541. Epub 2012 Feb 17.

49.

Anti-superoxide and anti-peroxynitrite strategies in pain suppression.

Janes K, Neumann WL, Salvemini D.

Biochim Biophys Acta. 2012 May;1822(5):815-21. doi: 10.1016/j.bbadis.2011.12.008. Epub 2011 Dec 19.

50.

Manganese superoxide dismutase, MnSOD and its mimics.

Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, Batinic-Haberle I.

Biochim Biophys Acta. 2012 May;1822(5):794-814. doi: 10.1016/j.bbadis.2011.12.002. Epub 2011 Dec 9. Review.

Supplemental Content

Loading ...
Support Center